Avid Bioservices Inc (CDMO)

[freethemice]

Thorpe and Shan deliver talks at the IBC 10th Annual Antibody Therapeutics meeting in San Diego, Dec 5, 2012.
http://www.ibclifesciences.com/antibodyeng/agenda-ther.xml
Development Status of Immunomodulatory Therapeutic Antibodies
8:00
Chairperson's Opening Remarks
Philip E. Thorpe, Ph.D., Professor of Pharmacology and The Serena S. Simmons Distinguished Chair, University of Texas Southwestern
11:00
Overcoming Immune Suppression in Tumors with Bavituximab: Preclinical Studies
Bavituximab is a monoclonal antibody that is proving safe and effective as a second-line therapy in advanced lung cancer patients. It targets the immunosuppressive lipid, phosphatidylserine, which becomes exposed on tumor blood vessels and tumor cells. Bavituximab causes MDSCs to differentiate into tumoricidal M1 macrophages that destroy the tumor vasculature and tumor cells by ADCC. It also causes immature dendritic cells in tumors to mature and present tumor antigens, resulting in the generation of tumor-specific cytotoxic T-cells.
Philip E. Thorpe, Ph.D., Professor of Pharmacology and The Serena S. Simmons Distinguished Chair, University of Texas Southwestern
11:30
Clinical Development of Bavituximab, a Phosphatidylserine (PS)-Targeting Monoclonal Antibody
Bavituximab, an investigational monoclonal antibody, localizes selectively on tumor vasculature, synergizes with chemotherapy, causes vascular shut down in tumors and reactivates innate and adaptive tumor immunity. In clinical trials to date, bavituximab has been well-tolerated both as a single agent and in combination with approved therapies. Bavituximab has demonstrated promising anti-tumor activity as an adjunct to standard chemotherapy in several solid tumor indications and is advancing to late-stage clinical development in non-small cell lung cancer.
Joseph Shan, MPH, Vice President, Clinical and Regulatory Affairs, Peregrine Pharmaceuticals, Inc.